3月20日 - ** 医疗保健公司Allurion Technologies
** 公司表示，初步数据显示，使用其设备以及诺和诺德（Novo Nordisk）的NOVOb.CO塞马鲁肽（semaglutide）低剂量治疗的患者，平均体重减轻了20.3%，瘦体重增加了68.5%
** 公司名为Allurion Balloon的设备占据胃部空间，旨在促进饱腹感并减少食物摄入量
** 该球囊无需手术，吞服后会在4个月后自然排空并排出体外——ALUR
** 公司表示，52名患者坚持服用GLP-1药物长达8个月
** 正在收集关于联合疗法的更多数据，预计将在即将举行的医学会议上公布——公司
** 2024年股价下跌了88.5%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.